8-KEarnings & ResultsExhibits & Filings

BIOGEN INC. 8-K Report, Financial Results (Jul 23, 2019)

Filed July 23, 2019For Securities:BIIB

Summary

Biogen Inc. (BIIB) filed an 8-K on July 23, 2019, to announce its second-quarter 2019 financial results. The core of this filing is the press release detailing the company's performance for the quarter ended June 30, 2019. Investors should note that this information is furnished and not deemed 'filed' under SEC regulations, meaning it doesn't carry the same liabilities or implications for future filings. The press release itself, attached as Exhibit 99.1, contains the detailed financial and operational data for the period. While the 8-K itself is a procedural filing, the accompanying press release is critical for understanding Biogen's recent financial health, revenue generation, and any forward-looking statements or guidance provided by management. Investors would need to refer to Exhibit 99.1 for specifics on revenue, earnings per share, operational highlights, and any significant events impacting the company's financial condition during Q2 2019.

Key Highlights

  • 1Biogen announced its Q2 2019 financial results on July 23, 2019, via a press release.
  • 2The press release is furnished as Exhibit 99.1 to the 8-K filing.
  • 3The filing pertains to the financial results for the quarter ended June 30, 2019.
  • 4Information is furnished under Item 2.02 and not considered 'filed' for Section 18 purposes.
  • 5The report does not introduce new financial statements but references an external press release.
  • 6Investors should review Exhibit 99.1 for detailed financial and operational performance data.
  • 7This filing serves as an official notification of the company's quarterly performance announcement.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce Biogen Inc.'s financial results for the second quarter ended June 30, 2019. It serves as a notification to investors and the market, primarily through the inclusion of a press release detailing these results.

The detailed financial results for Q2 2019 are contained within the press release issued by Biogen Inc. on July 23, 2019, which is furnished as Exhibit 99.1 to this 8-K filing and incorporated by reference.

No, the press release furnished with this 8-K is considered 'furnished' rather than 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. This means it does not automatically subject the company to the liabilities associated with 'filed' documents under that specific section.

The press release (Exhibit 99.1) is expected to contain key financial metrics such as revenue, earnings per share (EPS), net income, and potentially other operational highlights, segment performance, and any forward-looking statements or guidance provided by Biogen's management regarding future performance.